Cullinan Therapeutics said the U.S. Food and Drug Administration approved its investigation new drug application for CLN-978, a potential treatment for lupus. The biopharmaceutical company said the ...

Cullinan Therapeutics said the U.S. Food and Drug Administration approved its investigation new drug application for CLN-978, a potential treatment for lupus. The biopharmaceutical company said ...

Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...

Shares of NASDAQ CGEM opened at $16.22 on Wednesday. The stock has a market cap of $940.44 million, a price-to-earnings ratio of -5.30 and a beta of -0.13. Cullinan Therapeutics has a 52 week low ...

CAMBRIDGE, Mass. - Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) to proceed with Phase 1 clinical ...

CAMBRIDGE, Mass. - Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) to proceed with Phase 1 clinical trials ...

Cullinan Therapeutics has filed an investigational new drug application with the U.S. Food and Drug Administration (FDA) for CLN-978 for the treatment of systemic lupus erythematosus (SLE). Continue ...

Profund Advisors LLC increased its position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 26.8% during the 2nd quarter, according to its most recent 13F filing with the ...

BTIG analyst Julian Harrison reiterated a Buy rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...